Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

1742-4933-5-2 1742-4933 Research Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects Li Rongcheng lrch2001@163.com Fang Hanhua jdsfhh@sina.com Li Yanping gxymzx@126.com Liu Youping lyp95.53@163.com Pellegrini Michele michele.pellegrini@novartis.com Podda Audino audino.podda@novartis.com

Centre for Vaccine Clinical Research, Centers for Disease Prevention and Control of Guangxi Zhuang Autonomous Region, 18 Jinzhou Street, 530022 Nanning City, China

National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), Temple of Heaven, Beijing, China

Centers for Disease Prevention and Control of Wuzhou, Guangxi Zhuang Autonomous Region, China

Clinical Research Development and Medical Affairs, Novartis Vaccines and Diagnostics, Siena, Italy

Immunity & Ageing 1742-4933 2008 5 1 2 http://www.immunityageing.com/content/5/1/2 18289372 10.1186/1742-4933-5-2 18 9 2007 20 2 2008 20 2 2008 2008 Li et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine (Sub/MF59™; FLUAD^®, Novartis Vaccines) was evaluated among elderly Chinese subjects (≥ 60 years of age). After a preliminary Phase I, open-label study (n = 25) to assess safety 1–14 days post-vaccination, a comparative observer-blind, randomised, controlled clinical trial (n = 600) was performed to assess safety and immunogenicity versus a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal^®, Novartis Vaccines). Subjects were randomised (2:1) to receive Sub/MF59™ or Subunit.

Results

Both vaccines were well tolerated, with no vaccine-related serious adverse events reported during the Phase I trial. During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1–22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59™ recipients (P ≤ 0.005). Both vaccines induced a significant (P < 0.001) increase in geometric mean titres (GMTs) for the three strains tested, versus baseline; GMTs against A/H1N1, A/H3N2 and B were significantly higher in the Sub/MF59™ group (P = 0.034, P < 0.001 and P = 0.005, respectively). GMT ratios against A/H1N1, A/H3N2 and B were also significantly higher in the Sub/MF59™ group (P = 0.038, P < 0.001 and P = 0.006, respectively). Similarly, the percentage of subjects achieving seroprotection or seroconversion on Day 22 was greater for Sub/MF59™ recipients, reaching significance for A/H3N2 (P < 0.001).

Conclusion

MF59™-adjuvanted subunit influenza vaccine is well tolerated by elderly Chinese subjects and induces a higher level of immunogenicity than a non-adjuvanted subunit influenza vaccine in this population that is at high risk of influenza-related complications.

Clinical trial registry

http://www.clinicaltrials.gov, NCT00310648

Background

Influenza infection represents a considerable global burden, affecting 5–15% of the adult population during annual influenza epidemics 1. Each year, 3–5 million cases of severe illness and 250,000–500,000 deaths are thought to result from these epidemics worldwide 12.

South-east Asia is considered to be the global influenza epicentre, with several pandemic and epidemic strains known to have originated from China and Hong Kong since 1957 345. Furthermore, China is generally acknowledged as an area with a high influenza attack rate, due to the high population density and year-round circulation of the virus in tropical regions 67. In China, pneumonia and influenza combined ranks fourth in the leading causes of death in adults (≥ 40 years of age) 8.

Due to their weakened immune response, the elderly are at increased risk of influenza and its related complications 9. In China, the annual mortality rate for pneumonia and influenza has been reported to rise to 227.4/100,000 persons in the elderly (≥ 65 years of age), representing a 5-fold increase from the age-standardised annual mortality rate of 43.9/100,000 persons 8. Furthermore, during 1999, the reported number of influenza-associated deaths in Hong Kong from cardiorespiratory disease, pneumonia and influenza, chronic obstructive pulmonary disease and ischaemic heart disease was higher in the elderly (1697 deaths), compared with adults (205 deaths; 40–64 years of age) 10. Peaks in influenza circulation have been shown to coincide with increased mortality from these conditions, with the elderly accounting for approximately 70–90% of the associated deaths 10. In addition to an increased number of deaths 1011, the hospitalisation rate for pneumonia and influenza is also high in the elderly 12.

Influenza vaccine effectiveness has been studied extensively, mainly in temperate regions. Conventional influenza vaccines confer protection against laboratory-confirmed influenza in 70–90% of young adults (18–64 years of age) 1314; however, these vaccines are less effective (17–53%) in the elderly, due in part to the elderly's waning immunity 15. When evaluating vaccine response, however, it is important to also consider racial background. For example, among a racially diverse, healthy elderly population in the USA, a reduced response to influenza vaccine was observed among elderly African Americans, compared with elderly Caucasian and Latinos 16. Furthermore, racial differences in relation to vaccination have been observed in Taiwan among Han Chinese children compared with Aboriginal children; higher titres against hepatitis B vaccination were reported for Han Chinese children 17.

In Hong Kong, Taiwan and China, vaccination has been shown to offer protection against influenza 181920. Influenza vaccination prevented approximately 69% of influenza-related hospitalisation admissions in Hong Kong during the 2003–2004 winter season 19 and was strongly associated with a reduction in pneumonia, heart disease, stroke, diabetes mellitus and renal disease in Taiwan in 2001 20. Vaccine effectiveness, however, has also been reported to be lower in elderly Chinese people than in adult Chinese people (68.6% versus 74%, respectively) 18. Despite the availability of an effective vaccine, coverage rates are low in China; for example, the general vaccination rate among the urban population of Beijing is only 10.5%, falling to 7.9% for those ≥ 60 years of age 21. Thus, because currently available vaccines do not offer optimal protection in the elderly 1415 and vaccine coverage rates are low 21, elderly Chinese people are at increased risk of influenza and its related complications. As China has the world's largest population of elderly people (>80 million) 22, influenza represents a considerable health and economic burden.

To meet the global challenge presented by waning immunity in the elderly, vaccines that offer the elderly enhanced immunogenicity and increased clinical protection are required. Addition of the adjuvant MF59™ 23 to subunit influenza vaccine (MF59™-adjuvanted subunit influenza vaccine; FLUAD^®, Novartis Vaccines) has been shown to enhance the immune response and offer increased clinical protection in elderly subjects, compared with non-adjuvanted subunit influenza vaccine 242526. Furthermore, enhanced immunogenicity is observed in elderly subjects with underlying chronic conditions, who are at especially high risk of influenza and its complications 27. Vaccination of elderly subjects with the MF59™-adjuvanted subunit influenza vaccine also confers protection against a broader range of influenza virus strains than non-adjuvanted subunit influenza vaccine 2829 and has been associated with a reduced risk of hospitalisation for pneumonia and cerebrovascular disease in non-institutionalised elderly subjects 3031.

In China, the registration of FLUAD^®for use in elderly people is currently under consideration. For this reason, a randomised comparative trial was performed in a large cohort of elderly Chinese people to assess the safety and immunogenicity of FLUAD^®against a non-adjuvanted subunit influenza vaccine.

Results

All subjects (n = 25) enrolled in the Phase I open-label trial completed the safety evaluation. One subject was excluded from the analysis due to administration of Subunit vaccine, rather than Sub/MF59™. For the Phase II/III trial, the baseline characteristics of the study population were similar for the Sub/MF59™ and Subunit vaccine groups, with an equal match for gender, age and availability of current and past medical history. A total of 600 subjects were recruited in the subsequent Phase II/III trial and randomised to receive Sub/MF59™ (n = 400) or Subunit (n = 200) vaccine. Safety evaluation was completed for 589 subjects and serological analysis was performed for 554 subjects (Figure 1). The major reasons for patient withdrawal were refusal to continue the study (25 and 10 subjects receiving Sub/MF59™ and Subunit, respectively), a change in residence or hospital/being unable to receive follow-up as too busy (4 patients, 2 in each vaccine group) or other drop-out (6 and 1 subjects receiving Sub/MF59™ and Subunit, respectively). No subjects were withdrawn from the study because of an AE due to the study vaccines.

Figure 1

Subject participation in the Phase II/III trial

Subject participation in the Phase II/III trial.

Safety

Both vaccines were well tolerated by elderly subjects during the clinical trials. No vaccine-related serious adverse events (SAEs) were reported for Sub/MF59™ during the Phase I trial, which was a pre-requisite for continuation with the Phase II/III trial.

In the Phase II/III trial, the overall incidence of systemic reactions and AEs was generally similar between the Sub/MF59™ and Subunit groups; however, the incidence of local reactions was significantly (P = 0.012) higher in the Sub/MF59™ group compared with the Subunit group (24.0% versus 15.2%, respectively) (Table 1). Induration at the injection site was significantly (P < 0.05) more frequent in the Subunit group compared with the Sub/MF59™ group (2.5% versus 0.5%, respectively) (Table 2). Pain at the injection site and fever (axillary temperature >38°C) were significantly (P ≤ 0.005) more frequent in the Sub/MF59™ group compared with the Subunit group (10.2% versus 3.0% and 15.9% versus 7.6%, respectively) (Table 2). Local and systemic reactions were generally mild or moderate and transient. In particular, fever was mainly classed as mild or moderate in the Sub/MF59™ and Subunit groups and pain was classified as mild. No vaccine-related SAEs were reported during this large study for the Subunit group; however, a vaccine-related SAE (high fever) was reported for one subject (0.3%) in the Sub/MF59™ group (Table 1).

Table 1

Incidence of adverse events (AEs), adverse reactions and serious AEs (SAEs) for the two vaccine groups

Incidence, %(n)

P-value

Sub/MF59™ (n = 391)

Subunit (n = 198)

Local reactions

24.0(94)

15.2(30)

0.012

Systemic reactions

10.7(42)

9.6(19)

0.666

AEs

6.1(24)

6.6(13)

0.840

SAEs

1.0(4)

0.5(1)

0.668

Vaccine-related AEs (definitely, probably or possibly related to the vaccine)

3.8(15)

5.1(10)

0.490

Vaccine-related SAEs (definitely, probably or possibly related to the vaccine)

0.3(1)

0.0(0)

1.000

Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine

Table 2

Incidence of local and systemic reactions reported for the two vaccine groups

Sub/MF59™ %(n)

Subunit %(n)

Local reaction

Rash

0.0(0)

0.5(1)

Erythema

1.5(6)

1.5(3)

Induration

0.5(2)

2.5(5)*

Swelling

2.8(11)

1.0(2)

Pain

10.2(40)**

3.0(6)

Pruritus

1.3(5)

3.0(6)

Systemic reaction

Headache

3.6(14)

2.5(5)

Fever

15.9(62)**

7.6(15)

Tiredness

3.3(13)

1.0(2)

Diarrhoea

0.8(3)

2.0(4)

Vomiting

1.0(4)

1.0(2)

Myalgia

1.8(7)

0.5(1)

Cough

2.0(8)

2.0(4)

Angina

1.5(6)

1.0(2)

Watery nasal discharge

1.0(4)

1.0(2)

Skin disease (e.g. eczema)

0.0(0)

1.0(2)

Irritability

0.0(0)

0.5(1)

*P < 0.05 versus the Sub/MF59™ vaccine group; **P ≤ 0.005 versus the Subunit vaccine group

Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine

Immunogenicity

Pre-vaccination GMTs were similar for both vaccine groups against all three influenza strains tested. Baseline seroprotection rates were also similar between vaccine groups, with >97% of subjects in each vaccine cohort seroprotected against A/H1N1 (Sub/MF59™, 98.4%; Subunit, 97.3%), >18% against A/H3N2 (Sub/MF59™, 21.5%; Subunit, 18.7%) and >2% against B (Sub/MF59™, 2.2%; Subunit, 2.1%) prior to vaccination (Table 3).

Table 3

Pre- and post-vaccination seroprotection rate (percentage of subjects with haemagglutination inhibition titre ≥ 1:40)

Viral strain

Vaccination status

Sub/MF59™, % (n = 367)

Subunit, % (n = 187)

A/H1N1

Pre-vaccination

98.4

97.3

Post-vaccination

99.7

99.5

A/H3N2

Pre-vaccination

21.5

18.7

Post-vaccination

88.0*

72.2

Pre-vaccination

2.2

2.1

Post-vaccination

35.7

28.3

*P < 0.001 versus the Subunit group

Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine

At 3 weeks post-vaccination, significantly (P < 0.001) higher GMTs were reported for both vaccine groups versus baseline (data not shown); however, in the Sub/MF59™ group, post-vaccination GMTs against all three strains were significantly higher compared with the Subunit group (A/H1N1, 1439.01 versus 1197.39, respectively, P = 0.034; A/H3N2, 274.61 versus 110.85, respectively, P < 0.001; B, 16.59 versus 11.95, respectively, P = 0.005). Furthermore, GMT ratios (Day 22:Day 1) against the A/H1N1, A/H3N2 and B strains were significantly (P = 0.038, P < 0.001, P = 0.006, respectively) greater in the Sub/MF59™ group compared with the Subunit group (Figure 2). Following analysis of the data, including only those subjects who did not have seroprotective titres prior to vaccination, the same trend was found: higher post-vaccination GMTs were reported in the Sub/MF59™ group compared with the Subunit group for the A/H3N2 and B strains (P < 0.001 and P = 0.008, respectively), but not for A/H1N1 (Figure 3).

Figure 2

Geometric mean titre ratios (Day22:Day1) in all subjects in the Phase II/III trial

Geometric mean titre ratios (Day22:Day1) in all subjects in the Phase II/III trial.

Figure 3

Pre-vaccination (Day 1) and post-vaccination (Day 22) geometric mean titre against a) A/H1N1, b) A/H3N2 and c) B viral strains in subjects without pre-vaccination immunoprotection

Pre-vaccination (Day 1) and post-vaccination (Day 22) geometric mean titre against a) A/H1N1, b) A/H3N2 and c) B viral strains in subjects without pre-vaccination immunoprotection.

Post-vaccination, the percentage of subjects seroprotected against the A/H3N2 strain was significantly (P < 0.001) greater after vaccination with Sub/MF59™ compared with Subunit vaccination (Table 3). Although the seroprotection rate for all subjects against the A/H1N1 and B strains was higher in the Sub/MF59™ group, no significant difference was found between vaccine groups. In addition, a significantly (P < 0.001) greater number of previously unprotected elderly subjects in the Sub/MF59™ vaccine group demonstrated seroconversion against the A/H3N2 strain, compared with the Subunit group (85.1 versus 66.2%, respectively) (Table 4).

Table 4

Seroconversion rates (percentage of subjects with seroconversion^aor a significant increase in HI titres^bin subjects without pre-vaccination immunoprotection)

Seroconversion rates, %

Viral strain

Sub/MF59™

Subunit

A/H1N1^c

83.3

80.0

A/H3N2^d

85.1*

66.2

B^e

33.4

25.8

^aSeroconversion is defined as negative pre-vaccination serum (i.e. haemagglutinin inhibition [HI] titre <1:10) and post-vaccination HI titre ≥ 1:40; ^bSignificant increase is defined as ≥ 4-fold increase from non-negative (≥ 1:10) pre-vaccination HI titre; ^cNumber of subjects: Sub/MF59™, 6; Subunit, 5; ^dNumber of subjects: Sub/MF59™, 288; Subunit, 152; ^eNumber of subjects: Sub/MF59™, 359; Subunit, 183

*P < 0.001 versus the Subunit group

Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine

Discussion

This study has demonstrated that MF59™-adjuvanted subunit influenza vaccine is as well tolerated as non-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Although the number and incidence of some of the solicited local reactions in the Sub/MF59™ vaccine group was greater than in the Subunit group, they were generally mild or moderate and of short duration, and no subjects withdrew from the study due to safety concerns. Furthermore, the incidence of injection-site pain reported here was lower than has been reported in other studies 2527. Although the incidence of fever was higher than has been reported previously with MF59™-adjuvanted influenza vaccination 2527, the increased incidence was evident for both vaccines used in this study, rather than for the Sub/MF59™ vaccine only. The increase does not appear to be due to race, as in a previous study in elderly Chinese subjects 19 the incidence of fever was 0% following vaccination with non-adjuvanted influenza vaccine. These findings are in agreement with the published results of clinical trials conducted in elderly Caucasian populations in Europe 25. These trials supported registration of the vaccine in Europe, and concluded that the addition of MF59™ to subunit influenza vaccines does not cause clinically important changes in the safety profile of the influenza vaccine. To date, more than 30 million doses of the MF59™-adjuvanted subunit influenza vaccine have been sold, and it has demonstrated a good safety profile 32. Evaluation of post-marketing pharmacovigilance case reports (n = 385; September 1997 to April 2006) confirmed that vaccination with the MF59™-adjuvanted subunit influenza vaccine was associated with a very low frequency of adverse reactions 33.

Evaluation of the primary (pre- and post-vaccination GMTs and GMT ratio) and secondary (proportion of subjects with protective antibody titres [≥ 40] and those demonstrating seroconversion post-vaccination) immunogenicity parameters showed that both the Sub/MF59™ and Subunit vaccines were able to induce an immune response in elderly Chinese subjects. Significantly (P < 0.05) higher antibody titres were induced by the Sub/MF59™ vaccine compared with the Subunit vaccine. Furthermore, as for the safety profile, the immunogenicity results agree with the results of trials conducted in Europe 242527. For all three influenza strains tested, both the MF59™-adjuvanted and the non-adjuvanted vaccine met at least one criterion of the European Committee for Medicinal Products for Human Use (CHMP) criteria for the immunogenicity evaluation of seasonal influenza vaccines, as required for vaccine licensure 34. For both vaccines, the trend was for higher immunogenicity for the influenza A strains, compared to the B strain. It is of note that very high pre-vaccination titres were recorded in this study, especially for A/H1N1. This could be explained in part by the A/H1N1 vaccine strain (A/New Caledonia/20/99-like H1N1) being included in the vaccine formulation for several influenza seasons previous to the 2005–2006 season. Furthermore, from an epidemiological standpoint, influenza A strains are often the most dominant and the most relevant strains among adults and the elderly, with A/H1N1 having been the predominant circulating strain in the Guangxi region of China during the time before the trial was conducted.

It is well documented that levels of HI antibody titres correlate with seroprotection against influenza 35, thus it is expected that increased immunogenicity should lead to increased clinical protection from influenza. This approach has been widely used across the clinical trial programme for the MF59™-adjuvanted vaccine 25. During field studies in Europe, MF59™-adjuvanted vaccine has been shown to offer greater clinical protection against influenza-like illness compared with non-adjuvanted vaccine 26. Therefore, it is anticipated that MF59™-adjuvanted vaccine may also offer greater clinical protection in elderly Chinese subjects.

Results from trials using an MF59™-adjuvanted subunit influenza vaccine suggest that adjuvanted vaccination induces a greater immune response in elderly (≥ 60 years of age) Chinese subjects, and demonstrates a good tolerability profile, compared with a non-adjuvanted subunit influenza vaccine.

Conclusion

In conclusion, the study results strengthen support for the use of the MF59™-adjuvanted subunit influenza vaccine (FLUAD^®) among the elderly population in China.

Methods

Study design

A preliminary Phase I, open-label study was conducted in February-March 2006 to assess the safety of an MF59™-adjuvanted subunit influenza vaccine (Sub/MF59™; FLUAD®, Novartis Vaccines) in elderly Chinese subjects. The study recruited 25 Chinese subjects (≥ 60 years of age); of these, 24 subjects were administered Sub/MF59™ in follow-up sequence.

Following this safety trial, a Phase II/III randomised, observer-blind, controlled study was conducted to assess the safety and immunogenicity of Sub/MF59™ in a large cohort of elderly (≥ 60 years of age) Chinese subjects. Subjects were randomised (2:1) to receive either Sub/MF59™ (n = 400) or a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal®, Novartis Vaccines; n = 200). Both vaccines included the strains recommended for the 2005–2006 Northern hemisphere influenza season. Randomisation was achieved using the PEMS V2.1 statistical software (Statistics Teaching and Research Division, West China University of Medical Sciences; released January 1996). A 0.5 ml dose was administered intramuscularly in the deltoid region of the non-dominant arm.

Study population

Inclusion criteria

Subjects invited to participate in the trial were those ≥ 60 years of age, who were healthy and willing/able to provide written informed consent prior to study entry.

Exclusion criteria

Subjects with underlying disease chronic, such as tumours, autoimmune diseases, progressive artherosclerosis or complicated diabetes mellitus, chronic obstructive pulmonary disorder requiring oxygen therapy, acute or progressive liver or renal disease, or congestive heart failure; subjects with a known allergy to any vaccine components; subjects with laboratory-confirmed influenza or vaccinated against influenza within 6 months prior to enrolment; subjects who had received any other vaccine or investigational agent within 4 weeks prior to enrolment; subjects with current infectious disease, including those taking systemic antibiotics or antivirals.

Both the pivotal safety study and the subsequent trial were performed according to the ethical guidelines of the 1975 Declaration of Helsinki, Good Clinical Practice, and local laws. Before the trials started, the study protocol and informed consent form were approved by local ethics committees; all subjects signed an Informed Consent Form.

Objectives

Safety

Local and systemic reactions, including all adverse events (AEs), were monitored and recorded 14 days post-vaccination for the Phase I trial and 22 days post-vaccination for the Phase II/III trial, controlled study.

Immunogenicity

For the Phase II/III trial, blood samples were taken from all subjects pre-vaccination (Day 1) and post-vaccination (Day 22). Haemagglutinin inhibition (HI) antibody titres were measured in all samples. Primary parameters: Geometric mean titres (GMTs) against A/New Caledonia/20/99-like (A/H1N1), A/California/7/2004-like (A/H3N2) and B/Shanghai/361/2002-like influenza strains were measured for each vaccine pre- and post-vaccination (Day 1 and Day 22). The geometric mean titre ratio (GMR) of post-vaccination titres versus pre-vaccination titres was also reported. Secondary parameters: For each influenza strain, the number of subjects with seroprotective HI antibody titres (≥ 1:40) was also evaluated pre-vaccination and post-vaccination (Day 1 and Day 22), and the number of subjects achieving seroconversion (defined as ≥ 4-fold increase in HI titre from non-negative pre-vaccination titre [≥ 1:10] or a rise from <1:10 to a post-vaccination HI titre ≥ 1:40) post-vaccination (Day 22) was calculated.

Statistical methods, analysis and objectives

Data were analysed using the SAS V8.2 software. Statistical significance between vaccine groups for data describing the population's baseline characteristics was calculated using the Student's t-test and the chi-square test, or Fisher's exact test where necessary. Analysis of covariance was performed to calculate the confidence intervals for GMTs at Day 22, with GMT at Day 1 as covariate. Paired t-tests were performed to assess the difference between pre- and post-vaccination GMTs within each vaccine group. A P-value of <0.05 was considered to indicate statistical significance.

Competing interests

The study was funded by Novartis Vaccines, and Michele Pellegrini and Audino Podda are employees of Novartis Vaccines. The remaining authors declare that they have no competing interests.

Authors' contributions

RL and HF were responsible for the design, co-ordination and conduct of the clinical trial and the statistical analysis. RL, HF, YL, YL, MP and AP consulted the clinical results and prepared the manuscript. All authors read and approved the final manuscript.

WHO factsheet 211: Influenza World Health Organization 2003 http://who.int/mediacentre/factsheets/2003/fs211/en/print.html Accessed February 2007 Influenza vaccines: WHO position paper World Health Organization Wkly Epidemiol Rec 2005 80 279 287 16171031 Predictions for future human influenza pandemics Webster RG J Infect Dis 1997 176 S14 19 10.1086/514168 9240688 Analysis of the 1991–2000 influenza epidemic in Guangdong Province, China Huang P Ni H Shen G Zhou H Peng G Liu S Southeast Asian J Trop Med Public Health 2001 32 787 790 12041555 Influenza Nicholson KG Wood JM Zambon M Lancet 2003 362 1733 1745 10.1016/S0140-6736(03)14854-4 14643124 Severe acute respiratory syndrome and influenza: virus incursions from southern China Shortridge KF Am J Respir Crit Care Med 2003 168 1416 1420 10.1164/rccm.2310005 14668255 Influenza in tropical regions Viboud C Alonso WJ Simonsen L PLoS Med 2006 3 e89 1391975 16509764 10.1371/journal.pmed.0030089 Major causes of death among men and women in China He J Gu D Wu X Reynolds K Duan X Yao C Wang J Chen C-S Chen J Wildman RP Klag MJ Whelton PK N Engl J Med 2005 353 1124 1134 10.1056/NEJMsa050467 16162883 Immunosenescence: Role and measurement in influenza vaccine response among the elderly Targonski PV Jacobson RM Poland GA Vaccine 2007 25 3066 3069 10.1016/j.vaccine.2007.01.025 17275144 Influenza-associated mortality in Hong Kong Wong CM Chan KP Hedley AJ Peiris JS Clin Infect Dis 2004 39 1611 1617 10.1086/425315 15578360 Influenza in Taiwan: seasonality and vaccine strain match Hsieh YC Chen HY Yen JJ Liu PD Chang LY Lu CY Shao PL Lee CY Huang LM J Microbiol Immunol Infect 2005 38 238 243 16118670 Influenza-associated hospitalization in a subtropical city Wong CM Yang L Chan KP Leung G Chan KH Guan Y Lam TH Hedley AJ Peiris JSM PLoS Med 2006 3 e121 1391978 16515368 10.1371/journal.pmed.0030121 The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines Nichol KL Vaccine 2003 21 1769 1775 10.1016/S0264-410X(03)00070-7 12686092 Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007 Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep 2007 56 1 54 Antibody response to influenza vaccination in the elderly: A quantitative review Goodwin K Viboud C Simonsen L Vaccine 2006 24 1159 1169 10.1016/j.vaccine.2005.08.105 16213065 Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population Gardner EM Gonzalez EW Nogusa S Murasko DM Vaccine 2006 24 1609 1614 10.1016/j.vaccine.2005.09.058 16260072 Ethnic differences in immune responses to hepatitis B vaccine Hsu LC Lin SR Hsu HM Chao WH Hsieh JT Wang MC Lu CF Chang YH Ho MS Am J Epidemiol 1996 143 718 724 8651234 Assessment of effectiveness of Vaxigrip Jianping H Xin F Changshun L Bo Z Linxiu G Wei X Jiande S Vaccine 1999 17 Suppl 1 S57 58 10.1016/S0264-410X(99)00107-3 10471182 Immune response to influenza vaccination in community-dwelling Chinese elderly persons Hui SL Chu LW Peiris JSM Chan KH Chu D Tsui W Vaccine 2006 24 5371 5380 10.1016/j.vaccine.2006.04.032 16713661 Impact of influenza vaccination on major cause-specific mortality Wang C-S Wang S-T Lai C-T Lin L-J Chou P Vaccine 2007 25 1196 1203 10.1016/j.vaccine.2006.10.015 17097773 Rapid investigation of influenza-like cases incidence in Beijing urban area (2001) Li Q Wang L-J Wu H-Y Song T Chinese J Vaccines Immunization 2003 5 277 279 Demography of aging in China and the United States and the economic well-being of their older populations Kincannon CL He W West LA J Cross Cult Gerontol 2005 20 243 255 10.1007/s10823-006-9015-1 17041789 MF59™: a safe and potent adjuvant for human use Podda A Del Giudice G O'Hagan DT Immunopotentiators in modern vaccines Amsterdam: Academic Press Schijns VEJC, O'Hagan DT 2006 149 159 Comparison of three different influenza vaccines in institutionalised elderly Baldo V Menegon T Bonello C Floreani A Trivello R Mariutto Collaborative Group Vaccine 2001 19 3472 3475 10.1016/S0264-410X(01)00060-3 11348713 The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine Podda A Vaccine 2001 19 2673 2680 10.1016/S0264-410X(00)00499-0 11257408 Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy Iob A Brianti G Zamparo E Gallo T Epidemiol Infect 2005 133 687 693 10.1017/S0950268805003936 16050515 A new MF59™-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis Banzhoff A Nacci P Podda A Gerontology 2003 49 177 184 10.1159/000069172 12679609 Safety and immunogenicity of MF59™-adjuvanted influenza vaccine in the elderly De Donato S Granoff D Minutello M Lecchi G Faccini M Agnello M Senatore F Verweij P Fritzell B Podda A Vaccine 1999 17 3094 3101 10.1016/S0264-410X(99)00138-3 10462245 An MF59™-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine Del Giudice G Hilbert AK Bugarini R Minutello A Popova O Toneatto D Schoendorf I Borkowski A Rappuoli R Podda A Vaccine 2006 24 3063 3065 10.1016/j.vaccine.2006.01.015 16464520 Effectiveness of the MF59™-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age Puig-Barberà J Diez-Domingo J Hoyos SP Varea AB Vidal DG Vaccine 2004 23 283 289 10.1016/j.vaccine.2004.07.017 15530669 Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly Puig-Barberà J Díez-Domingo J Varea AB Chavarri GS Rodrigo JAL Pérez-Hoyos S Vidal DG Vaccine 2007 25 7313 7321 10.1016/j.vaccine.2007.08.039 17889411 MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection O'Hagan DT Expert Rev Vaccines 2007 6 699 710 10.1586/14760584.6.5.699 17931151 Tolerability and safety of an MF59-adjuvanted subunit influenza vaccine (FLUAD®) D'Agosto V Berardi S Burroni D Hennig R Poster presented at the 2nd International Conference on Influenza Vaccines for the World (IVW), Vienna, Austria 18–20 October 2006 Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 12 March 1997 Committee for Proprietary Medicinal Products (CPMP) http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf accessed November 2007 Determinants of immunity to influenza infection in man Potter CW Oxford JS Br Med Bull 1979 35 69 75 367490